Several preclinical and clinical literature sources have revealed that non-internalizing GRPR radioantagonists could successfully target and are sufficiently retained in overexpressed GRPR tumor lesions while rapidly clearing from physiologic tissues and organs (Maina et al., 2016; Baratto et al., 2018). Here, GRPR is linked to neoplasm.